NEURAMINIDASE INHIBITORS FOR THE SPECIFIC PREVENTION AND THERAPY OF INFLUENZA INFECTION
- Authors: Vasilyev Y.1
-
Affiliations:
- I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences
- Issue: Vol 25, No 2 (2014)
- Pages: 17-19
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115885
- ID: 115885
Cite item
Open Access
Access granted
Abstract
The review characterizes the efficacy and safety of neuraminidase inhibitors (oseltamivir, zanamivir) and discusses the resistance of influenza virus to these drugs. Emphasis is laid on the routes of administration for neuraminidase inhibitors and the novel drugs peramivir and laninamivir.
Keywords
Full Text
About the authors
Yu. Vasilyev
I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences
Email: yury.m.vasiliev@gmail.com
References
- Гендон Ю.З., Васильев Ю.М. Проблемы профилактики гриппа с помощью вакцин // Журн. микробиол. - 2011; 4: 115-24.
- Birnkrant D., Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza // New Engl. J. Med. - 2009; 361 (23): 2204-7.
- Brennan B., Davies B., Cirrincione-Dall G. et al. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers // Antimicrob. Agents Chemother. - 2012; 56 (9): 4729-37.
- Fraaij P., van der Vries E., Beersma M. et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection // J. Infect. Dis. - 2011; 204 (5): 777-82.
- Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships // Int. J. Risk Saf. Med. - 2008; 20: 5-36.
- Hama R., Jones M., Okushima H. et al. Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009 A/H1N1 influenza // Int. J. Risk Saf. Med. - 2011; 23 (4): 201-15.
- Jarhult J., Muradrasoli S., Wahlgren J. et al. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards // PLoS One. - 2011; 6 (9): 24742.
- Novak-Weekley S., Marlowe E., Poulter M. et al. Evaluation of the Cepheid Xpert Flu Assay for rapid identification and differentiation of influenza A, influenza A 2009 H1N1, and influenza B viruses // J. Clin. Microbiol. - 2012; 50 (5): 1704-10.
- Rodriguez A., Diaz E., Martin-Loeches I. et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza // J. Antimicrob. Chemother. - 2011; 66 (5): 1140-9.
- Shaw M., Palese P. Orthomyxoviridae. In: Knipe D., Howley P. (eds.). Fields Virology. Lippincott Williams & Wilkins, 2013.
- Shetty A., Peek L. Peramivir for the treatment of influenza // Expert Rev. Antiinfect. Ther. - 2012; 10 (2): 123-43.
- Sugaya N. Widespread use of neuraminidase inhibitors in Japan // J. Infect. Chemother. - 2011; 17 (5): 595-601.
- WHO. Vaccines against influenza WHO position pape, November 2012 // Wkly Epid. Rec. - 2012; 87 (74): 461-76.
- WHO. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. 2010, 32 p.
- Wright P., Neumann G., Kawaoka Y. Orthomyxoviruses. In: Knipe D., Howley P. (eds.). Fields Virology.Lippincott Williams & Wilkins, 2013.
Supplementary files
